New drug cocktail aims to shrink Hard-to-Treat breast tumors before surgery
NCT ID NCT07189884
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 24 times
Summary
This early-stage study tests whether adding two targeted drugs (pyrotinib and darcilib) to standard hormone therapy can shrink tumors before surgery in people with HR-positive, HER2-low breast cancer. The trial plans to enroll 33 patients with locally advanced disease. The main goal is to see how many patients have their tumor disappear or shrink significantly after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER (LABC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.